February 2025 – Page 15

Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude

3 months ago talkbio0Tagged Apretude, HIV Prevention, Lenacapavir, long-acting injectables, PREP gene, SmithKline Beecham, ViiV Healthcare

HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare

Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer

3 months ago talkbio0Tagged cell renal cell carcinoma, Conventional (Clear Cell) Renal Cell Carcinoma, Immunotherapy, Malignant neoplasm of kidney, Neoantigen, personalized cancer, phase 1 trial

personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial

AstraZeneca Shares Rise as China Investigation Impact Appears Limited

3 months ago talkbio0Tagged AstraZeneca, China, Evaluation, financial performance, import taxes, investor, Prices, Self Confidence

AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence

X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion

3 months ago talkbio0Tagged Antagonist muscle action, Chronic neutropenia, CXCR4 gene, strategic, WHIM syndrome, Xolremdi

X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring

Eli Lilly’s Zepbound Surpasses $4.9 Billion in First Year Sales Despite Q4 Shortfall

3 months ago talkbio0Tagged Advice, earnings, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Obesity, pharmaceutical revenue, Zepbound

Eli Lilly, Zepbound, obesity drug, Q4 2024 earnings, pharmaceutical revenue, GLP-1 medications, Mounjaro, 2025 guidance

Pfizer Appoints Jeffrey Legos as New Chief Oncology Officer

3 months ago talkbio0Tagged Cancer Research, Drug Industry, Jeffrey, Leadership Change, Legos, Neoplasms, Novartis, Pfizer

Pfizer, Jeffrey Legos, Novartis, oncology, pharmaceutical industry, leadership change, cancer research

AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset

3 months ago talkbio0Tagged Alexion, AstraZeneca, charge amounts, Complement Inactivating Agents, drug discontinuation, Drug Industry, Impaired, Vemircopan

AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry

Pfizer Taps Novartis Veteran Jeffrey Legos to Lead Oncology R&D Efforts

3 months ago talkbio0Tagged Cancer Research, Drug Industry, Jeffrey, Leadership, Legos, Neoplasms, Pfizer, R&D

Pfizer, Jeffrey Legos, oncology, R&D, leadership, cancer research, pharmaceutical industry

Trump Administration Targets Massive Cuts to Federal Health Workforce

3 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, federal, Government, health workers, healthcare agencies, Transplant Registry Unified Management Program, United States Food and Drug Administration

federal health workers, layoffs, Trump administration, HHS, FDA, healthcare agencies, workforce reduction, government downsizing

Hospital Group Seeks to Intervene in Lawsuit Against Lilly’s 340B Rebate Model

3 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, hospital intervention, Study models, United States Health Resources and Services Administration

340B Drug Pricing Program, Eli Lilly, rebate model, lawsuit, hospital intervention, Health Resources and Services Administration (HRSA), drug pricing